Genetic programming for computational pharmacokinetics in drug discovery and development

Genetic Programming and Evolvable Machines

Volumn 8, Issue 4, 2007, Pages 413-432

  Archetti, Francesco ^a,b   Lanzeni, Stefano ^a   Messina, Enza ^a   Vanneschi, Leonardo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Consorzio Milano Ricerche ^*  (Italy)

Author keywords

Computational pharmacokinetics; Drug discovery; Genetic programming

Indexed keywords

COMPUTATIONAL PHARMACOKINETICS; DRUG DISCOVERY; TOXIC EFFECTS;

COST REDUCTION; DRUG PRODUCTS; DRUG PRODUCTS PLANTS; DRUG THERAPY; GENETIC PROGRAMMING; TOXIC MATERIALS;

PHARMACOKINETICS;

EID: 36148998343     PISSN: 13892576     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10710-007-9040-z     Document Type: Article

References (40)

1. Kennedy, T.: Managing the drug discovery/development interface. Drug Discov. Today 2, 436-444 (1997)
2. Kola, I., Landis, J.: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-716 (2004)
3. Eddershaw, J.P., Beresford, A.P., Bayliss, M.K.: ADME/PK as part of a rational approach to drug discovery. Drug Discov. Today 9, 409-414 (2000)
4. van de Waterbeemd, H., Gifford, E.: ADMET in silico modeling: towards prediction paradise? Nat. Rev. Drug Discov. 2, 192-204 (2003)
5. Norinder, U., Bergstrom, C.A.S.: Prediction of ADMET properties. ChemMedChem 1, 920-937 (2006)
6. Tuffs, A.: Bayer faces shake up after Lipobay withdrawn. Br. Med. J. 323(7317), 828 (2001)
7. Koza, J.R.: Genetic Programming. The MIT Press, Cambridge, MA (1992)
8. Berezhkovskiy, L.M.: Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal. J. Pharmacokinet. Pharmacodyn. 33(5), 920-937 (2006)
9. van de Waterbeemd, H., Rose, S.: In: Wermuth, L.G. (ed.) The Practice of Medicinal Chemistry, 2nd ed., pp. 1367-1385. Academic Press (2003)
10. Todeschini, R., Consonni, V.: Handbook of Molecular Descriptors. Wiley-VCH, Weinheim (2000)
11. David, S., Wishart, Knox, C., Guo, A.C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., Woolsey, J.: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucl. Acids Res. 34: doi:10.1093/nar/ gkj067 (2006)
12. Yoshida, F., Topliss, J.G.: QSAR model for drug human oral bioavailability. J. Med. Chem. 43, 2575-2585 (2000)
13. Pintore, M., van de Waterbeemd, H., Piclin, N., ChrTtien, J.R.: Prediction of oral bioavailability by adaptive fuzzy partitioning. Eur. J. Med. Chem. 38(4), 427-31 (2003)
14. Frohlich, Wegner, J., Sieker, F., Zell, A.: Kernel functions for attributed molecular graphs-a new similarity based approach to ADME prediction in classification and regression. QSAR and Combinatorial Sci. 38(4), 427-431 (2003)
15. Andrews, C.W., Bennett, L., Yu, L.X.: Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharmacol. Res. 17, 639-644 (2000)
16. Feng, J., Lurati, L., Ouyang, H., Robinson, T., Wang, Y., Yuan, S., Young, S.S.: Predictive toxicology: benchmarking molecular descriptors and statistical methods. J. Chem. Inform. Comput. Sci. 43, 1463-1470 (2003)
17. Martin, T.M., Young, D.M.: Prediction of the acute toxicity (96-h LC50) of organic compounds to the fathead minnow (Pimephales promelas) using a group contribution method. Chem. Res. Toxicol. 14(10), 1378-1385 (2001)
18. van de Waterbeemd, H., Smith, D.A, Jones, B.C.: Lipophilicity in PK design:methyl, ethyl, futile. J. Comput. Aided Mol. Design 15, 273-286 (2001)
19. Colmenarejo, G., Alvarez-Pedraglio, A., Lavandera, J.L.: Chemoinformatic models to predict binding affinities to human serum albumin. J. Med. Chem. 44, 4370-4378 (2001)
20. Kratochwil, N.A., Huber, W., Muller, F., Kansy, F., Gerber, P.: Predicting plasma protein binding of drugs: a new approach. Biochem. Pharmacol. 64,1355-1374 (2002)
21. Zupan, J., Gasteiger, P.: Neural Networks in Chemistry and Drug Design: An Introduction, 2nd ed. Wiley (1999)
22. Greene, N.: Computer systems for the prediction of toxicity: an update. Adv. Drug Deliv. Rev. 54, 417-431 (2002)
23. Accelrys Inc.: The world leader in cheminformatics for drug development (2006). See www.accelrys.com
24. Pharma Algorithms Inc.: A company active in the field of ADMET predictions (2006). See www.ap-algorithms.com
25. Simulation Plus Inc.: A company that use both statistical methods and differential equations based simulations for ADME parameter estimation (2006). See www.simulationsplus.com
26. Langdon, W.B., Barrett, S.J.: Genetic Programming in data mining for drug discovery. Evolutionary Computing in Data Mining, 211-235 (2004)
27. Archetti, F., Lanzeni, S., Messina, E., Vanneschi, L.: Genetic programming for human oral bioavailability of drugs. In: Cattolico, M. (ed.) Proceedings of the 8th Annual Conference on Genetic and Evolutionary Computation, pp. 255-262. Seattle, Washington, USA (2006)
28. Tetko, I.V., Gasteiger, J., Todeschini, R., Mauri, A., Livingstone, D., Ertl, P., Palyulin, V.A., Radchenko, E.V., Zefirov, N.S., Makarenko, A.S., Tanchuk, V.Y., Prokopenko, V.V.: Virtual computational chemistry laboratory-design and description. J. Comput. Aided Mol. Design 19, 453-463 (2005). See www.vcclab.org
29. Keijzer, M.: Improving symbolic regression with interval arithmetic and linear scaling. In: Ryan, C., Soule, T., Keijzer, M., Tsang, E., Poli, R., Costa, E. (eds.) Genetic Programming, Proceedings of the 6th European Conference, EuroGP 2003, vol. 2610 of LNCS, pp. 71-83. Essex. Springer, Berlin, Heidelberg, New York (2003)
30. Hall, M.A.: Correlation-based feature selection for machine learning. Ph.D. thesis, Waikato University, Department of Computer Science, Hamilton, NZ (1998)
31. Jolliffe, I.T.: Principal Component Analysis, 2nd ed. Springer series in statistics (1999)
32. Weka: A multi-task machine learning software developed by Waikato University (2006). See www.cs.waikato.ac.nz/ml/weka/
33. Akaike, H.: Information theory and an extension of maximum likelihood principle. Proceedings of the 2nd International Symposium on Information Theory, Akademia Kiado (1973)
34. Rousseeuw, P.J., Leroy, A.M.: Robust Regression and Outlier Detection. Wiley, New York (1987)
35. Haykin, S.: Neural Networks: A Comprehensive Foundation. Prentice Hall, London (1999)
36. Smola Alex, J., Scholkopf, B.: A Tutorial on Support Vector Regression. Technical Report Technical Report Series- NC2-TR-1998-030, NeuroCOLT2, (1999)
37. REACH. Registration, Evaluation and Authorisation of Chemicals, 2006. http://ec.europa.eu/environment/chemicals/reach/reach_intro.htm
38. Vanneschi, L., Clergue, M., Collard, P., Tomassini, M., Vérel, S.: Fitness clouds and problem hardness in genetic programming. In: Deb, K., et al. (ed.) Proceedings of the Genetic and Evolutionary Computation Conference, GECCO'04, vol. 3103 of Lecture Notes in Computer Science, pp. 690-701. Springer, Berlin, Heidelberg, New York (2004)
39. Vanneschi, L., Tomassini, M., Collard, P., Vérel, S.: Negative slope coefficient. a measure to characterize genetic programming fitness landscapes. In: Collet, P., et al. (ed.) Genetic Programming, 9th European Conference, EuroGP2006, Lecture Notes in Computer Science, LNCS 3905, pp. 178-189. Springer, Berlin, Heidelberg, New York (2006)
40. Vanneschi, L.: Investigating problem hardness of real life applications. In: Riolo, R., et al. (eds.) Genetic Programming Theory and Practice. To appear (2007)